Juan Fernandez Alvarez

6552081, Apr 22, 2003

Nov 3, 2000

09/706404

Steven Freedman - Brighton MA
Juan G. Alvarez - Boston MA

Beth Israel Deaconess Medical Center, Inc. - Boston MA

A61K 3120

514560, 514558

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF gene, e. g. , cystic fibrosis, or a chronic inflammatory disorder, e. g. , ulcerative colitis, Crohns disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.

20040127567, Jul 1, 2004

Apr 8, 2003

10/410511

Steven Freedman - Brighton MA, US
Juan Alvarez - Boston MA, US

Beth Israel Deaconess Medical Center, Inc.

A61K031/202

514/560000

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF gene, e.g., cystic fibrosis, or a chronic inflammatory disorder, e.g., ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.

20110122487, May 26, 2011

May 11, 2005

11/596096

Lev T. Perelman - Brookline MA, US
Juan G. Alvarez - Boston MA, US
Mark Modell - Natick MA, US

Beth Israel Deaconess Medical Center, Inc. - Boston MA

G02B 21/00

359384, 359385

Apparatus including a broadband illumination source and a confocal optical system. The confocal optical system is configured and arranged to receive a portion of light projected onto an object by the broadband illumination source. The apparatus can include an illumination source, a confocal optical system, and at least one detector configured and arranged to receive angularly separated light corresponding to a confocal volume. There is also provided a light scattering spectroscopic device including a broadband illumination source, a two-dimensional detector, and a spectral separation device configured and arranged to receive scattered light from an object and to direct at least a portion of the scattered light onto the two-dimensional detector. The method and apparatus can combine confocal microscopy techniques with light scattering spectroscopy techniques to create a confocal light scattering spectroscopy (CLSS) system.

54439892, Aug 22, 1995

Oct 25, 1993

8/140569

Juan G. Alvarez - Boston MA
Jack Ludmir - Chestnut Hill MA

Beth Israel Hospital Association - Boston MA

G01N 3392

436 71

The present invention provides an accurate, rapid and precise methodology for assessing maturity of the lungs in a fetus prior to birth, especially for premature fetuses having a gestation period of 37 weeks or less. The methodology quantitatively measures a specific phosphoglyceride, dipalmitoyl phosphatidyl choline, in samples of amniotic fluid for the assessment of fetal lung maturity. The process enzymatically cleaves such phophoglycerides and preferably detects the resulting diacylglycerols by HPTLC-reflectance spectrodensitometry.

59358009, Aug 10, 1999

Sep 25, 1996

8/719756

Juan G. Alvarez - Boston MA

Beth Israel Deaconess Medical Center - Boston MA

G01N 3352
G01N 3353
G01N 2100

435 78

Assays and kits for identifying fertile sperm samples (e. g. for use in an assisted reproductive technology or as an indication of an ineffective male contraception (vasectomy)) and sub-fertile sperm samples (e. g. as an indication of a potentially infertile male donor or an effective male contraception) are disclosed.

58561960, Jan 5, 1999

Feb 16, 1995

8/388759

Juan G. Alvarez - Boston MA
Jack Ludmir - Chestnut Hill MA

Beth Israel Hospital - Boston MA

G01N 3392

436 71

Processes for detecting or quantitating a particular phosphoglyceride in a sample containing the phosphoglyceride and other lipids and clinical uses for the process (e. g. for diagnosing improperly functioning lungs and other conditions) are disclosed.

48111660, Mar 7, 1989

Jul 2, 1986

6/881427

Juan M. Alvarez - Medfield MA
Henry F. Breit - Attleboro MA
Steven E. Levy - Plainville MA
Premkumar R. Hingorany - Foxboro MA

Texas Instruments Incorporated - Dallas TX

H05K 720

361386

A heat dissipating pad or support member for mounting a semiconductor device in an electrical circuit has a metal core with a relatively low coefficient of thermal expansion preferably lower than that of the semiconductor device and has a thermally conducting, corrosion resistant metal coating with relatively greater thermal conductivity than the core. The thermally conducting coating is metallurgically bonded to top, bottom and two lateral surfaces of the core with a selected thickness to cooperate with the core in providing an outer surface portion of the member over the top of the core having an effective coefficient of thermal expansion substantially corresponding to the semiconductor device to reliably mount the semiconductor device thereon. The coating is thicker on at least one of the two lateral core surfaces so that heat collected from the semiconductor device at the top surface of the thermally conducting coating is efficiently transferrred via the lateral surface or surfaces on the core to the portion of the thermally conducting coating on the bottom surface of the member.

61806714, Jan 30, 2001

Feb 11, 1999

9/248471

Steven Freedman - Brighton MA
Juan G. Alvarez - Boston MA

Beth Israel Deaconess Medical Center, Inc. - Boston MA

A61K 3120

514560

A method of treating disorders in which DHA levels are affected is described. The method includes administering to a subject suffering from the disorder a therapeutically affective amount of DHA. This method is particularly useful in treating subjects suffering from a disorder characterized by a defect in the CF, gene, e. g. cystic fibrosis, or a chronic inflammatory disorder, e. g. , ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis. A method of ameliorating affects of cystic fibrosis in a newborn and a method of increasing surfactant levels in a fetus are also described.